^
Association details:
| Biomarker: | HDAC2 mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Excerpt:
The third patient with a response (Patient 8), who had biallelic somatic aberrations in HDAC2, received the study treatment for 62 weeks.
DOI:
10.1056/NEJMoa1506859
Trial ID:
